Orthocell on commercialisation path following revolutionary tendon regeneration trials

Labourers and athletes prone to shoulder injuries could have a significant solution after 89% of patients participating in Orthocell’s (ASX: OCC) tendon regeneration clinical trials, reported a pain-free return to work and recreation. 

The remaining 11% reported improved mobility and notably, none of the trial participants require further surgery two years on from the initial CelGro® tendon regeneration trial, or re-tore the surgically repaired rotator cuff tendon in the shoulder. 

“Rotator cuff tear is very common and repair can be challenging. An effective biological augment to surgical repair is increasingly desired by the orthopaedic community,” said Professor Allan Wang who was the leading orthopaedic surgeon for the trial.

“CelGro® has shown to improve tissue healing and may assist in reducing the surgical revision rate of the rotator cuff tendon.”

Following the highly successful trial results for Orthocell, the Company will seek commercialisation via regulatory approvals of CelGro® which could have a major impact on shoulder injuries, globally. 

Rotator cuff injuries are a common source of debilitating shoulder pain which has a material impact on the day-to-day strength of an individual in labour-intensive industries. In the United States alone,more than 500,000 rotator cuff surgical procedures are performed annually with Orthocell forecasting the addressable market for CelGro® to be US$1 billion per annum.

“We are extremely excited by the clinical follow up results indicating effectiveness of CelGro® in reducing the surgical revision rate,” said Orthocell Managing Director. Paul Anderson 

“CelGro® is proving to be a breakthrough soft tissue reconstruction platform technology with positive data announced now in nerve, tendon and bone applications.”